Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D09EIG
|
||||
| Former ID |
DNC005594
|
||||
| Drug Name |
Pyz6-D-Trp8-SRIF
|
||||
| Indication | Discovery agent | Investigative | [527585] | ||
| Formula |
C74H102N20O19S2
|
||||
| Canonical SMILES |
CC(C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O<br />)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=C<br />NC3=CC=CC=C32)CC4=CC=CC=C4)CC5=NC=CN=C5)CC(=O)N)CCCCN)N<br />C(=O)CNC(=O)C(C)N)C(=O)O)CO)C(C)O)CC6=CC=CC=C6)O
|
||||
| InChI |
1S/C74H102N20O19S2/c1-39(77)62(100)82-35-59(99)83-56-37-114-115-38-57(74(112)113)92-70(108)55(36-95)91-73(111)61(41(3)97)94-69(107)51(29-43-18-8-5-9-19-43)90-72(110)60(40(2)96)93-64(102)49(23-13-15-25-76)84-66(104)52(30-44-33-81-47-21-11-10-20-46(44)47)87-65(103)50(28-42-16-6-4-7-17-42)86-67(105)53(31-45-34-79-26-27-80-45)88-68(106)54(32-58(78)98)89-63(101)48(85-71(56)109)22-12-14-24-75/h4-11,16-21,26-27,33-34,39-41,48-57,60-61,81,95-97H,12-15,22-25,28-32,35-38,75-77H2,1-3H3,(H2,78,98)(H,82,100)(H,83,99)(H,84,104)(H,85,109)(H,86,105)(H,87,103)(H,88,106)(H,89,101)(H,90,110)(H,91,111)(H,92,108)(H,93,102)(H,94,107)(H,112,113)/t39-,40?,41?,48-,49+,50+,51-,52-,53-,54+,55-,56-,57-,60+,61+/m0/s1
|
||||
| InChIKey |
JDTSWTCDRKKTPI-DOAKGFBDSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Somatostatin receptor type 4 | Target Info | Inhibitor | [527585] | |
| Somatostatin receptor type 2 | Target Info | Inhibitor | [527585] | ||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| PathWhiz Pathway | Gastric Acid Production | ||||
| References | |||||